DUBLIN, Nov. 20, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/4c2378/2016_global) has announced the addition of the "2016 Global Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies" report to their offering.
This new report is a seven-countrystrategic analysis of the major business opportunities emerging in the automated microbiology market during the next five years. The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.
The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Companies Mentioned
- Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forensics/Lab Corp - Decode Genetics - Diad
For more information visit http://www.researchandmarkets.com/research/4c2378/2016_global
Media Contact:
Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article